Hypoplastic, haemolytic and renal anaemias

Drug Safety Update

 January 2018: Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)

 May 2015: Epoetin beta (NeoRecormon) increased risk of retinopathy in preterm infants cannot be excluded

 December 2014: Recombinant human erythropoietins: new advice for prescribing

 December 2014: Recombinant human erythropoietins: treating anaemia in cancer

NICE Guidance (see also drug-specific links below)

Eculizumab for treating atypical haemolytic uraemic syndrome

 TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy, November 2014

NG203: Chronic kidney disease: assessment & management, November 2021

TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria

TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome

TA807: Roxadustat for treating symptomatic anaemia in chronic kidney disease

TA1035: Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease

Epoetin Zeta (Retacrit) - Epoetin of choice at EKHUFT.

Retacrit has not been assessed for use at other sites.

All epoetin prescribed for patients undergoing dialysis is a HCD and reimbursed via NHSE. No Blu-teq completion required.

Pack
28 tablet
98 tablet
Pack
28 tablet
98 tablet

Eculizumab for treating atypical haemolytic uraemic syndrome

Pack
1 vial

For prescribing at a specialist centre only, not MTW

 TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria

 TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome

Pack
1 vial
Pack
1 vial
Pack
1 vial
  • On Formulary Preferred
  • On Formulary Second Line
  • On Formulary Third Line
  • Specialist Initiation
  • Secondary Care Only
  • Not Approved for Formulary